Printed From BioPortfolio.com
Lilly's stomach cancer drug meets main goal, but fails to improve survival rate
18:28 EST 8 Dec 2017 | Reuters
(Reuters) - Eli Lilly & Co said on Friday a late-stage trial testing its drug, Cyramza, as a gastric cancer treatment met the main goal of preventing the disease from advancing, but failed its secondary target of improving overall survival rates.
Original Article: Lilly's stomach cancer drug meets main goal, but fails to improve survival rate
